Clinical trial · Observational
Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy
NCT03535987CI-TRIAL-00082731completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| myocardial PET imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- To determine the feasibility of using myocardial PET imaging
- interventionNames
- Device: myocardial PET imaging
Primary outcomes (1)
- measure
- number of subjects who successfully complete Rb-82 myocardial PET Imaging assessments
- timeFrame
- 12-18 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 51 Years
Show eligibility criteria text
Inclusion Criteria: * Either clinically localized prostate cancer or biochemically-recurrent prostate cancer patients who are planned for at least 6 months ADT with a GnRH agonist and curative-intent radiation therapy per their oncologic providers. * Over 50 years of age. Calculated 10-year Framingham General Cardiovascular Risk Score of ≥10% at the time of planned initiation of ADT. * Patients must be able to read and understand English. * Participants must sign the informed consent form. Exclusion Criteria: * Prior treatment with GnRH agonist therapy. * History of active asthma or other reactive airway disease. * Ischemic cardiac event (myocardial infarction, unstable angina) within the preceding 6 months.
References
Publications (0)
Data not yet available
No reference posted for this study.